PD1)/程序性细胞死亡配体1(programmed cell death ligand 1,PD-L1)单克隆抗体在新辅助免疫治疗联合化疗方案中显著地提高了早期可手术的NSCLC患者的主要病理缓解(major pathological response,MPR)率和无事件生存(even-free survival,EFS)率...
[2] Spigel DR, Faivre-Finn C, Gray JE, et al. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer[J]. J Clin Oncol. 2022 Apr 20;40(12):1301-1311. doi: 10.1200...
PD1)/程序性细胞死亡配体1(programmed cell death ligand 1,PD-L1)单克隆抗体在新辅助免疫治疗联合化疗方案中显著地提高了早期可手术的NSCLC患者的主要病理缓解(major pathological response,MPR)率和无事件生存(even-free survival,EFS)率,已成为早期可手术的NSCLC患者的标准治疗方案之一。
The investigators found an overall survival (OS) rate of 32 percent with standard radiotherapy treatment with 60 Gray (Gy) radiation delivered in 30 fractions, compared to 23 percent OS with 74 Gy in 37 fractions. The NCI estimates that 5-year survival rates in this population range fro...
较传统的化疗方案,靶向治疗和免疫治疗极大地提高了晚期NSCLC患者的生存率,5年总生存(overall survival,OS)率达到了20%~30%[1-4]。在晚期的NSCLC取得成功后,靶向治疗和免疫治疗进一步拓展到早中期可手术的NSCLC的围术期治疗中。2023年围术期NSCLC的治疗取得了重大进展,国内外的程序性细胞死亡受体1(programmed cell ...
In recent decades, the overall five-year survival rate for patients diagnosed with lung cancer increased from 11% to 15% on average across EU countries. Improved survival rates are due, in part, to earlier det...
resulting in a lower five-year survival rate [1]. Therefore, systemic treatment should be administered as early as possible to eliminate or avoid micro-metastatic lesions to the maximum extent. In recent decades, significant progress has been made in the treatment of NSCLC, particularly in targete...
Concurrent CRT is considered the preferred treatment for patients who are fit, as it leads to higher 5-year survival rates, albeit at the cost of a higher rate of reversible oesophagitis. In recent phase III trials delivering concurrent CRT to doses between 60 and 66 Gy, the incidence of...
(IIIB) TNanyM12725 Sloan-KetteringCancercenter Stage5-YearSurvivalRate (%) StageI(n=539) 76 T1N0M084 T2N0M068 StageII(n=214) T1-2N1M047 T3N0(胸壁受侵)56 T3N0(隆突受侵)36 T3N0(纵隔受侵)29 StageIIIN2(手术、n=151) 30 StageIIIN2(化疗+手术、n=89) 26 INSCLC •首选肺叶切除...
ECOG1594研究提示,第三代化疗药物疗效达到瓶颈,顺铂和紫杉醇、顺铂和吉西他滨、顺铂和多西他赛或卡铂和紫杉醇之间的疗效没有明显差异,患者中位总生存期(overall survival, OS)为7.9个月(95%CI: 7.3~8.5个月),2年OS率为11%(95%CI...